1. Home
  2. VYNE vs WYY Comparison

VYNE vs WYY Comparison

Compare VYNE & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • WYY
  • Stock Information
  • Founded
  • VYNE 2003
  • WYY 1991
  • Country
  • VYNE United States
  • WYY United States
  • Employees
  • VYNE N/A
  • WYY N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • WYY EDP Services
  • Sector
  • VYNE Health Care
  • WYY Technology
  • Exchange
  • VYNE Nasdaq
  • WYY Nasdaq
  • Market Cap
  • VYNE 35.7M
  • WYY 35.6M
  • IPO Year
  • VYNE 2018
  • WYY 1998
  • Fundamental
  • Price
  • VYNE $1.85
  • WYY $2.87
  • Analyst Decision
  • VYNE Strong Buy
  • WYY Strong Buy
  • Analyst Count
  • VYNE 2
  • WYY 1
  • Target Price
  • VYNE $6.88
  • WYY $7.00
  • AVG Volume (30 Days)
  • VYNE 224.4K
  • WYY 33.9K
  • Earning Date
  • VYNE 05-08-2025
  • WYY 04-15-2025
  • Dividend Yield
  • VYNE N/A
  • WYY N/A
  • EPS Growth
  • VYNE N/A
  • WYY N/A
  • EPS
  • VYNE N/A
  • WYY N/A
  • Revenue
  • VYNE $501,000.00
  • WYY $142,571,749.00
  • Revenue This Year
  • VYNE N/A
  • WYY $7.92
  • Revenue Next Year
  • VYNE N/A
  • WYY $10.18
  • P/E Ratio
  • VYNE N/A
  • WYY N/A
  • Revenue Growth
  • VYNE 18.16
  • WYY 34.47
  • 52 Week Low
  • VYNE $1.44
  • WYY $1.83
  • 52 Week High
  • VYNE $4.30
  • WYY $6.25
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 53.21
  • WYY 39.25
  • Support Level
  • VYNE $1.76
  • WYY $2.50
  • Resistance Level
  • VYNE $1.93
  • WYY $3.25
  • Average True Range (ATR)
  • VYNE 0.16
  • WYY 0.45
  • MACD
  • VYNE 0.06
  • WYY -0.01
  • Stochastic Oscillator
  • VYNE 83.67
  • WYY 51.52

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.

Share on Social Networks: